A RARE CASE OF A PATIENT WITH A METATYPICAL BASAL CELL CARCINOMA OF THE FOREHEAD TREATED SUCCESSFULLY WITH ELLIPTICAL EXCISION

G. Tchernev¹, J. Ananiev² and J. C. Cardoso³

¹Polyclinic for Dermatology and Venerology, University Hospital Lozenetz, "Saint Kliment Ohridski" University, Sofia, Bulgaria
²Department of General and Clinical Pathology, Medical Faculty, Trakia University, Stara Zagora, Bulgaria
³Dermatology Department, University Hospital of Coimbra, Coimbra, Portugal

Summary: We present a rare case of a 72-year-old patient with an ulcerative lesion localized to the left forehead, appearing 3 months prior to clinical presentation. Biopsy revealed a metatypical basal cell carcinoma. Treatment consisted of wide local excision. There was no sign of recurrence or metastasis after a 12-month follow-up period. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) make up 95% of the most common type of cancer in the world, the non-melanoma skin cancer. BCC is known for its potential to be locally invasive, while SCC for its potential to metastasize in lymph nodes. Metatypical basal cell carcinoma (MTBC) is a rare tumor that combines clinical and histopathological features of both BCC and SCC. The gold standard for diagnosis lies in the histopathologic examination. Clinical examination alone does not suffice.

Key words: metatypical, basal cell carcinoma, histopathology, basosquamous carcinoma, surgery

INTRODUCTION

Non-melanoma skin cancer is the most common type of cancer in the world. Basal cell carcinoma (BCC) is the most common malignancy of the skin, accounting for 80% of all cutaneous cancers [1, 2]. Risk factors include high cumulative ultraviolet light (UV) exposure, and having Fitzpatrick skin type I or II [3]. BCCs develop from outer root hair follicle epithelium with preference of the head-and-neck region [3, 4]. Loss of function mutations in patched homologue-1 tumor suppressor (PTCH-1) or gain of function mutations activating
PCTH-1 receptor smoothened (SMO) can be identified in the majority of BCCs. One third of BCCs occur in non-sun-exposed areas. Nodular BCC is the most common type of BCC, and classically presents with a raised and rolled border, often with fragility and intermittent bleeding [3, 4].

Metatypical basal cell carcinoma (MTBCC), also referred as basosquamous carcinoma, is a rare variant of BCC, which shares clinical and histopathologic characteristics of both BCC and SCC [5]. MTBCC was first described by MacCormac in 1910 as a histological variant in a series of rodent ulcers, in which basal cell and squamous cell tumors were present side by side without a transition zone [6]. As such, it is considered a particularly aggressive form of BCC, with increased risk of metastases and higher recurrence rates than common BCC. MTBCC can disseminate by perineural invasion and metastasize in up to 5% [7-10]. The terminology of this tumor is still controversial, while the literature data regarding its incidence, pathogenesis, natural course, and optimal treatment are somewhat scarce and not well defined [5].

**CLINICAL CASE**

Anamnesis. The patient was a 72-year-old Caucasian male with a history of extensive sun exposure who presented with a 4-month history of a lesion on the right forehead (Fig.1a). The lesion was initially painless, and slowly growing, with occasional spontaneous bleeding. Ulceration occurred approximately 1 month after the lesion first appeared.

Clinical examination revealed a 1.8 cm plaque, growing primarily endophytically, with central ulceration, located in the right frontoparietal scalp (Figs 1a, 1b). Multiple surrounding actinic keratoses were present (Figs 1a, 1b).

![Image](1a)

![Image](1b)

![Image](1c)

![Image](1d)

**Fig. 1.** (a) Ulcerated nodule of the forehead; (b) Planning the surgical procedure; (c) Appearance after removal of stitches; (d) Outcome after 3 months follow-up

A rare case of a patient with a metatypical...
Histopathological examination. The tumor islands had a reticulated configuration composed of an incomplete outer layer of dark-staining basal cells and an inner layer, actually representing the majority of the tumor, featuring larger and lighter staining cells (Figs. 2a, 2b, 2c). This can be regarded as an intermediate type of MTBC [9].

![Fig. 2. (a) Trabeculae of tumor cells with a basaloid appearance; (b), (c) The cells at the periphery of tumor islands have a more dark-staining appearance, whereas in the center they assume a more pale-staining quality; note the retraction artefact](image)

![Fig. 2. (c) Detail of the deep part of the tumor, showing the infiltrative growth pattern, in close proximity with the sebaceous glands](image)

Imaging/Laboratory investigations. Chest X-ray, MRI of the head and neck, abdominal ultrasound, sonographic evaluation of the lymph nodes of the neck, axilla, supraclavicular region, and groins did not reveal any gross nodal or visceral metastases.

All routine serum laboratory measurements including complete blood count and liver function tests were normal.

Treatment and Outcome. The tumor was removed with elliptical excision under local anesthesia (Figs. 1a-1d). This was followed by primary closure with single
A rare case of a patient with a metatypical basal cell carcinoma (MTBCC) or basosquamous carcinoma defines a histopathological variant that comprises features of both basal cell and squamous cell carcinomas, with or without a transition zone between them [9]. Throughout the literature the terms “metatypical” and “basosquamous” are often used interchangeably, although some authors argue that basosquamous carcinoma is more appropriate as reflecting the likely pathogenesis of the tumor [10].

MTBCC can be classified histologically into two subtypes: intermediate and mixed [7]. The intermediate-subtype MTBCC is characterized by the presence of tumor lobules or nests composed of basaloïd cells that mature into paler cells with more abundant cytoplasm [5, 7]. The mixed-subtype MTBCC is described as having features typical of basal cell carcinoma coexisting with areas of conglomerated squamous cells, and often with the presence of focal keratinization, commonly referred as “squamous pearls” [8, 11]. Both histologically and clinically, MTBCC can be considered a BCC/SCC tumor hybrid [5, 7, 8, 11].

Immunohistochemical analysis is useful in the diagnosis of MTBCC, as areas of basal cell carcinoma are Ber-EP4 and AE1/AE3 positive, while areas of squamous cell carcinoma are AE1/AE3 and CAM5.2-positive, with variable staining with epithelial membrane antigen [13, 14]. The transition zone shows in most of the cases a decline of staining for Ber-EP4a [13, 14].

Recently, Cigna et al. performed a retrospective study of 312 patients with MTBCC localized on face and scalp [15]. They found a strong correlation between mixed subtype and ulceration and intermediate subtype and positive surgical margin. Perineural infiltration is not uncommon among these tumors. They concluded that the intermediate type of MTBCC seems more aggressive [15].

Compared to other types of BCC, MTBCC is considered to have a higher incidence of recurrence and increased incidence of metastasis [5]. Recurrence rate of 10% to 48% have been reported [5, 7, 10, 12, 16]. The metastatic rate can be as high as 5% to 7.4%, which seems to a quantum leap compared to BCC in general with less than one per mille [5, 7, 10, 12, 16]. Currently there are no established guidelines regarding the treatment of MTBCC. There is general consensus, that MTBCC should be treated as an aggressive form of BCC [5, 6, 10]. It is recommended that wider surgical margins be taken than for basal cell carcinoma, with Mohs micrographic surgery being an excellent surgical option having lower recurrence rates than classic excision [17]. Mohs is particularly indicated for high-risk locations such as the ears, midface, recurrent or large tumors, and tissue preser-
vation in cosmetically sensitive areas [19]. Close clinical follow-up for 5 years has been recommended.

Vismodegib is an oral inhibitor of the Hedgehog pathway approved by the US Food and Drug Administration. It is the first systemic treatment for patients with locally advanced or metastatic basal cell carcinoma that is not amenable to surgery and radiation [20]. It can be an alternative in MTBCC not treatable by surgery.

CONCLUSIONS

The diagnosis of metatypical basal cell carcinoma requires a thorough medical history and a cutaneous biopsy, followed by exact histopathologic verification, and following appropriate surgical excision. MTBC is regarded as an aggressive form of BCC, with a higher recurrence rate and increased risk of metastasis [7]. This has direct implications for treatment and follow-up of patients.

REFERENCES:


Address for correspondence:
Assoc. Professor Dr. Georgi Tchernev
Polyclinic for Dermatology and Venerology
Saint Kliment Ohridski University
Medical Faculty
University Hospital Lozenetz
1 Koziak St.
1407 Sofia
Bulgaria
00359 885 588 424
e-mail: georgi_tchernev@yahoo.de